 Laurie Carr
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 10 | 2021 | 2222 | 1.550 |
Why?
| | Neuroendocrine Cells | 2 | 2016 | 30 | 1.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 928 | 0.720 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 975 | 0.600 |
Why?
| | Lung Diseases, Obstructive | 1 | 2016 | 40 | 0.530 |
Why?
| | Research Report | 1 | 2016 | 75 | 0.500 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 339 | 0.460 |
Why?
| | Antineoplastic Agents | 3 | 2013 | 1897 | 0.450 |
Why?
| | Medical Oncology | 1 | 2016 | 228 | 0.450 |
Why?
| | Octreotide | 1 | 2013 | 25 | 0.430 |
Why?
| | Neuroendocrine Tumors | 1 | 2013 | 85 | 0.400 |
Why?
| | Quinazolines | 1 | 2013 | 243 | 0.400 |
Why?
| | Sirolimus | 1 | 2013 | 181 | 0.390 |
Why?
| | Lung Diseases | 2 | 2016 | 703 | 0.390 |
Why?
| | Iodine | 1 | 2010 | 18 | 0.360 |
Why?
| | Pyrazoles | 1 | 2013 | 364 | 0.360 |
Why?
| | Pyridines | 1 | 2013 | 425 | 0.350 |
Why?
| | Pyrroles | 1 | 2010 | 183 | 0.330 |
Why?
| | Lung | 4 | 2021 | 3593 | 0.330 |
Why?
| | Electronic Health Records | 1 | 2016 | 802 | 0.330 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 648 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2016 | 834 | 0.320 |
Why?
| | Carcinoma | 1 | 2010 | 199 | 0.320 |
Why?
| | Indoles | 1 | 2010 | 306 | 0.310 |
Why?
| | Loss of Heterozygosity | 1 | 2007 | 41 | 0.300 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 263 | 0.290 |
Why?
| | Hyperplasia | 2 | 2016 | 164 | 0.250 |
Why?
| | Forced Expiratory Volume | 2 | 2018 | 476 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2326 | 0.230 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 642 | 0.190 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2021 | 25 | 0.180 |
Why?
| | Disease Progression | 2 | 2018 | 2392 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-yes | 1 | 2019 | 2 | 0.170 |
Why?
| | Dasatinib | 1 | 2019 | 46 | 0.170 |
Why?
| | Humans | 15 | 2021 | 114925 | 0.170 |
Why?
| | Aging | 1 | 2007 | 1621 | 0.150 |
Why?
| | Spirometry | 1 | 2018 | 225 | 0.150 |
Why?
| | Vital Capacity | 1 | 2018 | 257 | 0.140 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 14 | 0.130 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 18 | 0.130 |
Why?
| | Machine Learning | 1 | 2019 | 318 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 686 | 0.120 |
Why?
| | Neoplasm Staging | 3 | 2016 | 1180 | 0.120 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 26 | 0.120 |
Why?
| | Survival Rate | 1 | 2018 | 1644 | 0.110 |
Why?
| | Bronchiolitis | 1 | 2015 | 81 | 0.110 |
Why?
| | Erlotinib Hydrochloride | 1 | 2013 | 65 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4427 | 0.110 |
Why?
| | Everolimus | 1 | 2013 | 61 | 0.110 |
Why?
| | Biopsy | 1 | 2016 | 1045 | 0.100 |
Why?
| | Registries | 2 | 2021 | 1760 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 718 | 0.100 |
Why?
| | Aged | 5 | 2021 | 19120 | 0.100 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 24 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2316 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2018 | 6363 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 2011 | 163 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.090 |
Why?
| | Female | 7 | 2019 | 59571 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2018 | 3008 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 347 | 0.090 |
Why?
| | Carcinoma, Medullary | 1 | 2010 | 13 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 954 | 0.090 |
Why?
| | Tomography, Emission-Computed | 1 | 2010 | 58 | 0.090 |
Why?
| | Chronic Disease | 1 | 2016 | 1593 | 0.090 |
Why?
| | Communication | 1 | 2016 | 747 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2010 | 121 | 0.090 |
Why?
| | Bronchoscopy | 1 | 2011 | 246 | 0.090 |
Why?
| | Biomarkers | 1 | 2019 | 3418 | 0.080 |
Why?
| | Treatment Failure | 1 | 2010 | 332 | 0.080 |
Why?
| | Global Health | 1 | 2011 | 288 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 265 | 0.080 |
Why?
| | United States | 2 | 2018 | 12209 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2011 | 256 | 0.080 |
Why?
| | Middle Aged | 4 | 2019 | 26801 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 530 | 0.080 |
Why?
| | Male | 6 | 2019 | 55655 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2015 | 2199 | 0.070 |
Why?
| | Time Factors | 1 | 2018 | 6125 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1458 | 0.070 |
Why?
| | Adult | 4 | 2019 | 30604 | 0.070 |
Why?
| | Cellular Senescence | 1 | 2007 | 153 | 0.070 |
Why?
| | DNA Repair | 1 | 2007 | 186 | 0.070 |
Why?
| | Mutation | 2 | 2016 | 3353 | 0.060 |
Why?
| | DNA Damage | 1 | 2007 | 357 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 8637 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1361 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2010 | 1699 | 0.050 |
Why?
| | Infant | 1 | 2016 | 7936 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2016 | 12543 | 0.050 |
Why?
| | Patient Identification Systems | 1 | 2021 | 17 | 0.050 |
Why?
| | Incidental Findings | 1 | 2021 | 77 | 0.040 |
Why?
| | Reference Standards | 1 | 2019 | 159 | 0.040 |
Why?
| | Oncogenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1355 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 623 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 13 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 35 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2012 | 63 | 0.030 |
Why?
| | Remission Induction | 1 | 2012 | 233 | 0.020 |
Why?
| | Neutropenia | 1 | 2012 | 125 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 169 | 0.020 |
Why?
| | Frail Elderly | 1 | 2012 | 105 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 190 | 0.020 |
Why?
| | Fatigue | 1 | 2012 | 296 | 0.020 |
Why?
| | Piperazines | 1 | 2012 | 313 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 378 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1220 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1856 | 0.020 |
Why?
| | Animals | 1 | 2007 | 31837 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 4524 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2012 | 9105 | 0.010 |
Why?
|
|
Carr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|